Related references
Note: Only part of the references are listed.A novel immunoregulatory axis of NKT cell subsets regulating tumor immunity
Jay A. Berzofsky et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Matrix metalloproteinase 8 contributes to solubilization of IL-13 receptor α2 in vivo
Weiguo Chen et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2008)
Tuning sensitivity to IL-4 and IL-13: differential expression of IL-4Rα, IL-13Rα1, and γc regulates relative cytokine sensitivity
Ilkka S. Junttila et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
Expression of glioma-associated antigens in pediatric brain stem and non-brain stem gliomas
Hideho Okada et al.
JOURNAL OF NEURO-ONCOLOGY (2008)
Targeting IL-13Rα2-positive cancer with a novel recombinant immunotoxin composed of a single-chain antibody and mutated Pseudomonas exotoxin
Mitomu Kioi et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Spontaneous immune responses against glioma-associated antigens in a long term survivor with malignant glioma
Ryo Ueda et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2007)
Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: Phase 1 study of final safety results
Michael A. Vogelbaum et al.
NEUROSURGERY (2007)
Endogenous metalloprotease solubilizes IL-13 receptor α2 in airway epithelial cells
Mikiko Matsumura et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: A report by the Cintredekin Besudotox Intraparenchymal Study Group
Sandeep Kunwar et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Allergy-driven alternative splicing of IL-13 receptor α2 yields distinct membrane and soluble forms
Yasuhiro Tabata et al.
JOURNAL OF IMMUNOLOGY (2006)
N-linked glycosylation of IL-13Rα2 is essential for optimal IL-13 inhibitory activity
Mitomu Kioi et al.
FASEB JOURNAL (2006)
Interleukin-13 receptor α2 chain -: A potential biomarker and molecular target for ovarian cancer therapy
Mitomu Kioi et al.
CANCER (2006)
Intratumoral therapy with IL13-PE38 results in effective CTL-mediated suppression of IL-13Rα2-expressing contralateral tumors
Koji Kawakami et al.
CLINICAL CANCER RESEARCH (2006)
Identification of interleukin-13 receptor α2 peptide analogues capable of inducing improved antiglioma CTL responses
Junichi Eguchi et al.
CANCER RESEARCH (2006)
Characterization of a novel human tumor antigen interleukin-13 receptor α2 chain
K Kawakami et al.
CANCER RESEARCH (2006)
IL-13 signaling through the IL-13 alpha 2 receptor is involved in induction of TGF-beta 1 production and fibrosis
S Fichtner-Feigl et al.
NATURE MEDICINE (2006)
Genes that mediate breast cancer metastasis to lung
AJ Minn et al.
NATURE (2005)
Aberrant stat3 signaling by interleukin-4 in malignant glioma cells:: Involvement of IL-13Rα2
SO Rahaman et al.
CANCER RESEARCH (2005)
Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma
IF Parney et al.
JOURNAL OF NEUROSURGERY (2005)
Optimization of expression and purification of two biologically active chimeric fusion proteins that consist of human interleukin-13 and Pseudomonas exotoxin in Escherichia coli
BH Joshi et al.
PROTEIN EXPRESSION AND PURIFICATION (2005)
IL-13 receptor α 2 down-modulates granulomatous inflammation and prolongs host survival in schistosomiasis
MM Mentink-Kane et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Fibrotic disease and the TH1/TH2 paradigm
TA Wynn
NATURE REVIEWS IMMUNOLOGY (2004)
Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells
KS Kahlon et al.
CANCER RESEARCH (2004)
Opposing roles for IL-13 and IL-13 receptor α2 in health and disease
MM Mentink-Kane et al.
IMMUNOLOGICAL REVIEWS (2004)
Enhanced interleukin (IL)-13 responses in mice lacking IL-13 receptor α 2
N Wood et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
IL-13 receptor-targeted cytotoxin cancer therapy leads to complete eradication of tumors with the aid of phagocytic cells in nude mice model of human cancer
K Kawakami et al.
JOURNAL OF IMMUNOLOGY (2002)
Cytokine receptor as a sensitizer for targeted cancer therapy
K Kawakami et al.
ANTI-CANCER DRUGS (2002)
Stat6-deficient mice develop airway hyperresponsiveness and peribronchial fibrosis during chronic fungal asthma
K Blease et al.
AMERICAN JOURNAL OF PATHOLOGY (2002)
Apoptotic pathways of cell death induced by an interleukin-13 receptor-targeted recombinant cytotoxin in head and neck cancer cells
M Kawakami et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2002)
In vivo overexpression of IL-13 receptor α2 chain inhibits tumorigenicity of human breast and pancreatic tumors in immunodeficient mice
K Kawakami et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
Gene transfer of interleukin 13 receptor α2 chain dramatically enhances the antitumor effect of IL-13 receptor-targeted cytotoxin in human prostate cancer xenografts
K Kawakami et al.
CANCER GENE THERAPY (2001)
Studies of murine schistosomiasis reveal interleukin-13 blockade as a treatment for established and progressive liver fibrosis
MG Chiaramonte et al.
HEPATOLOGY (2001)
Identification of distinct roles for a dileucine and a tyrosine internalization motif in the interleukin (IL)-13 binding component IL-13 receptor α2 chain
K Kawakami et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
The interleukin-13 receptor α2 chain:: an essential component for binding and internalization but not for interleukin-13-induced signal transduction through the STAT6 pathway
K Kawakami et al.
BLOOD (2001)
Mutation and functional analysis of IL-13 receptors in human malignant glioma cells
M Kawakami et al.
ONCOLOGY RESEARCH (2001)
NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway
M Terabe et al.
NATURE IMMUNOLOGY (2000)
Cutting edge: STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma
S Ostrand-Rosenberg et al.
JOURNAL OF IMMUNOLOGY (2000)